pomalidomide has been researched along with Anemia in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 11 (78.57) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Boyle, J; Bright, S; Capra, M; Chraniuk, D; Currie, B; Delimpasi, S; Dimopoulos, MA; He, W; Hungria, VTM; Leleu, X; Li, J; Li, M; Low, M; Maiolino, A; Masszi, T; Matsumoto, M; McKeown, A; Mikala, G; Opalinska, J; Osipov, I; Pappa, V; Perera, S; Radinoff, A; Roy-Ghanta, S; Sule, N; Weisel, K | 1 |
| Einsele, H; Grathwohl, D; Kortüm, KM; Krummenast, F; Leicht, HB; Meckel, K; Nickel, K; Rasche, L; Steinhardt, MJ; Zhou, X | 1 |
| Cervantes, F; Martinez-Trillos, A | 1 |
| Cortes, J; Daver, N; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; O'Brien, S; Pierce, S; Quintas-Cardama, A; Shastri, A; Verstovsek, S; Zhou, L | 1 |
| Guglielmelli, P; Vannucchi, AM | 1 |
| Cervantes, F; Gale, RP; Hudgens, S; Khan, ZM; Mesa, R; Passamonti, F; Rivera, C; Tefferi, A; Tencer, T; Verstovsek, S | 1 |
| Cortes, J; Daver, N; Jabbour, E; Kadia, T; Kantarjian, H; Newberry, K; Pemmaraju, N; Pierce, S; Shastri, A; Verstovsek, S; Zhou, L | 1 |
| Birgegård, G | 1 |
| Ross, DM | 1 |
| Blanc, L; Dulmovits, BM; Hom, J; Mohandas, N; Narla, A | 1 |
| Barosi, G; Bekele, BN; Cervantes, F; Deeg, HJ; Gale, RP; Gisslinger, H; Kantarjian, HM; Kvasnicka, HM; Mesa, RA; Paquette, RL; Passamonti, F; Rivera, CE; Roboz, GJ; Tefferi, A; Thiele, J; Vardiman, JW; Verstovsek, S; Zhang, Y | 1 |
| Hogan, WJ; Hussein, K; Litzow, MR; Mesa, RA; Pardanani, AD; Schwager, S; Tefferi, A; Wu, W | 1 |
| Begna, KH; Hogan, WJ; Litzow, MR; McClure, RF; Mesa, RA; Pardanani, A; Tefferi, A | 1 |
| Begna, K; Finke, C; Lasho, T; Pardanani, A; Tefferi, A | 1 |
3 review(s) available for pomalidomide and Anemia
| Article | Year |
|---|---|
Myelofibrosis: an update on current pharmacotherapy and future directions.
Topics: Age Factors; Androgens; Anemia; Humans; Immunologic Factors; Janus Kinase 2; Mutation; Nitriles; Primary Myelofibrosis; Prognosis; Pyrazoles; Pyrimidines; Radiotherapy; Splenomegaly; Stem Cell Transplantation; Thalidomide | 2013 |
Does anything work for anaemia in myelofibrosis?
Topics: Androgens; Anemia; Blood Transfusion; Erythropoietin; Hematinics; Humans; Immunosuppressive Agents; Interferons; Lenalidomide; Nitriles; Oxymetholone; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Thalidomide | 2014 |
Characterization, regulation, and targeting of erythroid progenitors in normal and disordered human erythropoiesis.
Topics: Anemia; Animals; Biomarkers; Cell Differentiation; Cell Proliferation; Cell Self Renewal; Erythroid Precursor Cells; Erythropoiesis; Glucocorticoids; Humans; Immunologic Factors; Immunophenotyping; Phenotype; Thalidomide | 2017 |
8 trial(s) available for pomalidomide and Anemia
| Article | Year |
|---|---|
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local | 2023 |
Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.
Topics: Aged; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Primary Myelofibrosis; Prospective Studies; Thalidomide; Treatment Outcome | 2013 |
Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia.
Topics: Anemia; Bayes Theorem; Double-Blind Method; Female; Glucocorticoids; Humans; Male; Myeloproliferative Disorders; Neoplasms; Prednisone; Primary Myelofibrosis; Quality of Life; Thalidomide; Treatment Outcome | 2014 |
Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
Topics: Aged; Aged, 80 and over; Anemia; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Prednisone; Primary Myelofibrosis; Survival Analysis; Thalidomide; Treatment Outcome | 2014 |
Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Double-Blind Method; Female; Glucocorticoids; Hematinics; Humans; Immunologic Factors; Male; Middle Aged; Prednisone; Primary Myelofibrosis; Prospective Studies; Thalidomide | 2009 |
Phase1/-2 study of Pomalidomide in myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anti-Inflammatory Agents; Female; Humans; Immunosuppressive Agents; Male; Maximum Tolerated Dose; Middle Aged; Prednisolone; Primary Myelofibrosis; Thalidomide | 2010 |
A phase-2 trial of low-dose pomalidomide in myelofibrosis.
Topics: Aged; Aged, 80 and over; Anemia; Basophils; Erythrocyte Transfusion; Female; Humans; Janus Kinase 2; Male; Middle Aged; Mutation; Primary Myelofibrosis; Thalidomide | 2011 |
Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Chemokine CCL2; Cytokines; Female; Humans; Interleukin-15; Interleukin-8; Janus Kinase 1; Janus Kinase 2; Male; Middle Aged; Mutation; Predictive Value of Tests; Primary Myelofibrosis; Receptors, Interleukin-2; Thalidomide; Treatment Outcome | 2011 |
3 other study(ies) available for pomalidomide and Anemia
| Article | Year |
|---|---|
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Leukopenia; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pneumonia; Progression-Free Survival; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Thrombocytopenia; Treatment Outcome | 2020 |
Struggling with myelofibrosis-associated anemia.
Topics: Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Primary Myelofibrosis; Thalidomide | 2013 |
Responses to pomalidomide and placebo in myelofibrosis-related anaemia.
Topics: Anemia; Humans; Immunologic Factors; Primary Myelofibrosis; Thalidomide | 2017 |